NA
ALNY icon

Neuburgh Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Neuburgh Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$214K Hold
2,656
– – 0.01% 658
2019
Q2 		$193K Sell
2,656
-480
-15% -$36.8K 0.01% 698
2019
Q1 		$293K Sell
3,136
-32
-1% -$2.68K 0.01% 581
2018
Q4 		$231K Sell
3,168
-30,480
-91% -$2.34M 0.01% 600
2018
Q3 		$2.94M Sell
33,648
-3,376
-9% -$340K 0.09% 181
2018
Q2 		$3.65M Buy
37,024
+8,848
+31% +$878K 0.12% 156
2018
Q1 		$3.36M Buy
+28,176
New +$3.63M 0.12% 156

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Neuburgh Advisers's ALNY Position: Q3 2019 in Review

Neuburgh Advisers held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 2,656 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #658.

Neuburgh Advisers first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $3.65M in Q2 2018. 280 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

  • Neuburgh Advisers held 2,656 shares of Alnylam Pharmaceuticals worth $214K as of Q3 2019.
  • Neuburgh Advisers left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
  • Alnylam Pharmaceuticals made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #658 holding.
  • Neuburgh Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
  • Neuburgh Advisers's Alnylam Pharmaceuticals position peaked at $3.65M in Q2 2018.
  • 280 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.